Acrobiosystems Co Ltd
SZSE:301080

Watchlist Manager
Acrobiosystems Co Ltd Logo
Acrobiosystems Co Ltd
SZSE:301080
Watchlist
Price: 43 CNY -4.04%
Market Cap: 5.1B CNY
Have any thoughts about
Acrobiosystems Co Ltd?
Write Note

Acrobiosystems Co Ltd
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Acrobiosystems Co Ltd
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Acrobiosystems Co Ltd
SZSE:301080
Current Portion of Long-Term Debt
ÂĄ20.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Current Portion of Long-Term Debt
ÂĄ358.8m
CAGR 3-Years
57%
CAGR 5-Years
43%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Current Portion of Long-Term Debt
ÂĄ451.9m
CAGR 3-Years
200%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Current Portion of Long-Term Debt
ÂĄ13.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Current Portion of Long-Term Debt
ÂĄ30.8k
CAGR 3-Years
-81%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Current Portion of Long-Term Debt
ÂĄ61.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Acrobiosystems Co Ltd
Glance View

Market Cap
5.1B CNY
Industry
Biotechnology

ACROBiosystems Co., Ltd. engages in the development of biomedicine and bio-protein technology. The company is headquartered in Beijing, Beijing and currently employs 397 full-time employees. The company went IPO on 2021-10-18. The firm's main products are recombinant proteins and detection services, as well as kits, antibodies, fillers, culture media and other related products. The firm's main products and services are applied to research and development (R&D) and production links such as early drug discovery and verification, drug screening and optimization, development and optimization of diagnostic reagents, preclinical and clinical trials, drug production process and process control (CMC) of tumors, autoimmune diseases, cardiovascular diseases, infectious diseases and other diseases.

Intrinsic Value
48.56 CNY
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Acrobiosystems Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
20.1m CNY

Based on the financial report for Dec 31, 2023, Acrobiosystems Co Ltd's Current Portion of Long-Term Debt amounts to 20.1m CNY.

What is Acrobiosystems Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
6%

Over the last year, the Current Portion of Long-Term Debt growth was 6%.

Back to Top